• ABT-263 (Navitoclax): Precision Bcl-2 Targeting in Complex C

  2026-05-18

  Explore the advanced scientific basis and translational impact of ABT-263 (Navitoclax) as a potent Bcl-2 inhibitor in cancer biology. This in-depth analysis integrates recent mechanistic insights and practical assay guidance, offering unique perspectives on complex tumor models.

• N6-Methyl-dATP: Precision Tool for Epigenetic DNA Replicatio

  2026-05-18

  N6-Methyl-dATP empowers researchers to dissect DNA replication fidelity and methylation effects with unmatched specificity. Its unique N6-methyl modification offers novel insights into polymerase selectivity, epigenetic regulation, and disease modeling—delivering a level of mechanistic clarity that conventional dATP analogs cannot match.

• 3-Methyladenine: Applied Autophagy Inhibition in Cell Assays

  2026-05-17

  3-Methyladenine (3-MA) from APExBIO enables precise, reproducible autophagy inhibition in cancer and virology research. This guide delivers actionable protocols, advanced troubleshooting, and insights that bridge bench workflows with cutting-edge discoveries in phosphoinositide 3-kinase signaling.

• ONX-0914 (PR-957): Precision Immunoproteasome Inhibition in

  2026-05-16

  ONX-0914 (PR-957) enables researchers to dissect immune pathways with high selectivity, minimizing off-target effects in autoimmune and neuroinflammatory models. Its robust cytokine blockade and proven in vivo efficacy make it indispensable for translational immunology and advanced synaptic plasticity studies.

• PDHA1 Acetylation Regulates Cuproptosis and Drug Resistance

  2026-05-15

  This study uncovers how PDHA1-mediated acetylation suppresses copper-dependent cell death (cuproptosis), thereby driving resistance to anti-androgen therapy in castration-resistant prostate cancer (CRPC). By connecting mitochondrial metabolism to epigenetic regulation and copper handling, the findings highlight PDHA1 as a promising target to restore treatment sensitivity.

• Applied Use Cases of 12-O-tetradecanoyl phorbol-13-acetate (

  2026-05-15

  12-O-tetradecanoyl phorbol-13-acetate (TPA) remains the gold-standard PKC activator for dissecting ERK/MAPK pathway signaling in cancer biology and redox research. This guide delivers stepwise protocols, troubleshooting insights, and experimental strategies powered by APExBIO’s high-purity TPA, enabling reproducible results across in vitro and in vivo models.

• PF-562271 HCl in Precision Oncology: Beyond FAK Inhibition

  2026-05-14

  Explore how PF-562271 HCl, a potent FAK/Pyk2 inhibitor, is redefining cancer research by enabling predictive response studies and translational assay development. This in-depth analysis uniquely bridges advanced kinase targeting with the latest radiopathomics innovations in tumor biology.

• ABT-263 (Navitoclax): Precision Tools for Senescence and Agi

  2026-05-14

  Explore how ABT-263 (Navitoclax) empowers next-generation apoptosis and cellular senescence research. This article uniquely bridges molecular mechanism, epigenetic assay optimization, and practical guidance for aging and cancer biology applications.

• ISRIB (trans-isomer): A Next-Gen PERK Inhibitor for ER Stres

  2026-05-13

  ISRIB (trans-isomer) is redefining ER stress research and fibrosis modeling by specifically inhibiting the PERK pathway and ATF4 translation, enabling high-precision apoptosis and memory assays. Its robust performance in cellular and in vivo models makes it a standout choice for researchers investigating integrated stress response mechanisms and therapeutic interventions.

• L1023 Anti-Cancer Compound Library for High-Throughput Oncol

  2026-05-13

  The L1023 Anti-Cancer Compound Library empowers cancer researchers with a rigorously curated repertoire of 1164 bioactive small molecules, uniquely formatted for high-throughput screening and rapid pathway interrogation. Its diversity and validated selectivity accelerate the discovery of actionable targets—such as PLAC1 in clear cell renal cell carcinoma—streamlining translational workflows from hit identification to mechanistic elucidation.

• CXCR4-Targeted Theranostic Strategies in Lymphoma Research

  2026-05-12

  This review synthesizes recent advances in CXCR4-targeted imaging and therapy for lymphoma, highlighting how overexpression of CXCR4 promotes tumor survival and chemoresistance. The study details the diagnostic and therapeutic utility of diverse CXCR4 ligands, offering insight into molecular imaging integration and precision oncology.

• H2O2 Controls Aluminum Resistance via STOP1 Oxidation in Ara

  2026-05-12

  This study uncovers how hydrogen peroxide (H2O2) accumulation under aluminum stress drives the oxidation and degradation of the STOP1 transcription factor, thereby decreasing Al resistance in Arabidopsis. These findings clarify the regulatory network linking mitochondrial redox state, protein stability, and plant stress adaptation, with direct relevance for dissecting translation-dependent mechanisms in plant biology.

• Re-Evaluating ACE Inhibitors: Selectivity Among Aminopeptida

  2026-05-11

  This study rigorously compares the inhibitory effects of commonly used ACE inhibitors and related metallopeptidase inhibitors on three key mammalian cell surface aminopeptidases (AP-A, AP-N, AP-W). The findings clarify the enzyme selectivity of these compounds, which is critical for accurate interpretation in hypertension and cardiovascular research, and inform the choice of inhibitors in experimental design.

• Optimized hiPSC Platelet Differentiation: Protocol and Insig

  2026-05-11

  This study presents a systematically optimized protocol for differentiating functional platelets from human induced pluripotent stem cells, reducing production time and cost while increasing yield and platelet quality. The findings offer a practical foundation for scalable ex vivo platelet manufacturing with implications for cell therapy and gene editing.

• Amiloride (MK-870): Advancing Translational Ion Channel Rese

  2026-05-10

  This thought-leadership article reveals how Amiloride (MK-870), a dual ENaC and uPAR inhibitor, empowers translational researchers to bridge mechanistic ion channel insights with real-world disease models. Integrating evidence from emerging immunogenic nanoliposome studies and established sodium transport protocols, we provide strategic guidance for leveraging Amiloride in cystic fibrosis, hypertension, and cellular endocytosis research. The article offers a critical evaluation of current experimental standards, protocol nuances, and the evolving competitive landscape, while situating APExBIO's Amiloride as the gold-standard tool for impactful discovery.

455 records 18/31 page Previous Next First page 上5页 1617181920 下5页 Last page